CY1112971T1 - Σουλφοναμιδια 2-(υποκατεστημενο-αμινο)-βενζοθειαζολης ως αναστολεις της πρωτεασης ηiv - Google Patents

Σουλφοναμιδια 2-(υποκατεστημενο-αμινο)-βενζοθειαζολης ως αναστολεις της πρωτεασης ηiv

Info

Publication number
CY1112971T1
CY1112971T1 CY20121100429T CY121100429T CY1112971T1 CY 1112971 T1 CY1112971 T1 CY 1112971T1 CY 20121100429 T CY20121100429 T CY 20121100429T CY 121100429 T CY121100429 T CY 121100429T CY 1112971 T1 CY1112971 T1 CY 1112971T1
Authority
CY
Cyprus
Prior art keywords
amino
substituted
inhibitors
present
benzothiothiazole
Prior art date
Application number
CY20121100429T
Other languages
Greek (el)
English (en)
Inventor
Kock Herman De
Tim Hugo Maria Jonckers
Paul Jozef Gabriel Maria Boonants
Stefaan Julien Last
Inge Dierynck
Judith Eva Baumeister
Klooster Gerben Albert Eleutherius Van´T
Original Assignee
Tibotec Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharmaceuticals filed Critical Tibotec Pharmaceuticals
Publication of CY1112971T1 publication Critical patent/CY1112971T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CY20121100429T 2006-06-23 2012-05-08 Σουλφοναμιδια 2-(υποκατεστημενο-αμινο)-βενζοθειαζολης ως αναστολεις της πρωτεασης ηiv CY1112971T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06116003 2006-06-23
EP07765554A EP2035432B1 (en) 2006-06-23 2007-06-22 2-(Substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

Publications (1)

Publication Number Publication Date
CY1112971T1 true CY1112971T1 (el) 2016-04-13

Family

ID=37596252

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100429T CY1112971T1 (el) 2006-06-23 2012-05-08 Σουλφοναμιδια 2-(υποκατεστημενο-αμινο)-βενζοθειαζολης ως αναστολεις της πρωτεασης ηiv

Country Status (30)

Country Link
US (1) US8202887B2 (enExample)
EP (1) EP2035432B1 (enExample)
JP (1) JP5232776B2 (enExample)
KR (1) KR101419320B1 (enExample)
CN (1) CN101479275B (enExample)
AP (1) AP2069A (enExample)
AR (1) AR061619A1 (enExample)
AT (1) ATE544769T1 (enExample)
AU (1) AU2007262943B2 (enExample)
BR (1) BRPI0713487B1 (enExample)
CA (1) CA2653233C (enExample)
CL (1) CL2007001826A1 (enExample)
CY (1) CY1112971T1 (enExample)
DK (1) DK2035432T3 (enExample)
EA (1) EA016387B1 (enExample)
ES (1) ES2381129T3 (enExample)
IL (1) IL195381A (enExample)
JO (1) JO2841B1 (enExample)
MX (1) MX2009000160A (enExample)
MY (1) MY146805A (enExample)
NZ (1) NZ573286A (enExample)
PE (1) PE20080342A1 (enExample)
PL (1) PL2035432T3 (enExample)
PT (1) PT2035432E (enExample)
SI (1) SI2035432T1 (enExample)
TW (1) TWI415851B (enExample)
UA (1) UA96445C2 (enExample)
UY (1) UY30416A1 (enExample)
WO (1) WO2007147884A1 (enExample)
ZA (1) ZA200810350B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3090B1 (ar) 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
CN103140474A (zh) 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
US9024038B2 (en) * 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1370543B1 (en) * 2001-02-14 2006-10-25 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
AR037797A1 (es) * 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
BR0305717A (pt) * 2002-08-02 2004-09-28 Tibotec Pharm Ltd Inibidores da protease do hiv 2-amino-benzotiazol sulfonamida de amplo espectro
PT1670448E (pt) * 2003-09-30 2008-02-11 Tibotec Pharm Ltd Sulfonamidas inibidoras de hcv

Also Published As

Publication number Publication date
ES2381129T3 (es) 2012-05-23
PL2035432T3 (pl) 2012-07-31
JO2841B1 (en) 2014-09-15
ZA200810350B (en) 2010-05-26
DK2035432T3 (da) 2012-05-14
UA96445C2 (ru) 2011-11-10
UY30416A1 (es) 2008-01-31
CL2007001826A1 (es) 2008-01-18
AP2069A (en) 2009-12-08
PE20080342A1 (es) 2008-04-25
EP2035432A1 (en) 2009-03-18
SI2035432T1 (sl) 2012-06-29
TW200817416A (en) 2008-04-16
BRPI0713487A8 (pt) 2018-01-02
EP2035432B1 (en) 2012-02-08
AU2007262943B2 (en) 2012-04-12
ATE544769T1 (de) 2012-02-15
KR101419320B1 (ko) 2014-07-14
IL195381A (en) 2013-01-31
CA2653233C (en) 2015-09-29
NZ573286A (en) 2011-09-30
US20090209583A1 (en) 2009-08-20
AR061619A1 (es) 2008-09-10
CA2653233A1 (en) 2007-12-27
JP5232776B2 (ja) 2013-07-10
JP2009541272A (ja) 2009-11-26
WO2007147884A1 (en) 2007-12-27
MX2009000160A (es) 2009-01-23
AU2007262943A1 (en) 2007-12-27
AP2008004679A0 (en) 2008-12-31
EA200970052A1 (ru) 2009-04-28
PT2035432E (pt) 2012-04-24
EA016387B1 (ru) 2012-04-30
KR20090024257A (ko) 2009-03-06
IL195381A0 (en) 2009-08-03
BRPI0713487A2 (enExample) 2012-11-13
TWI415851B (zh) 2013-11-21
BRPI0713487B1 (pt) 2022-07-26
HK1125633A1 (en) 2009-08-14
MY146805A (en) 2012-09-28
CN101479275B (zh) 2012-03-07
CN101479275A (zh) 2009-07-08
US8202887B2 (en) 2012-06-19

Similar Documents

Publication Publication Date Title
EA200970052A1 (ru) 2-(замещенные амино)бензотиазолсульфонамидные ингибиторы вич-протеазы
MA32369B1 (fr) Composes de benzene sulfonamide thiazole et oxazole
DK2064348T3 (da) Profilering af receptorfamilie
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
BRPI0815920A2 (pt) Composto, composição farmacêutica, e, uso do composto.
CL2008000862A1 (es) Compuestos derivados de triazolonas, inhibidores no nucleosidos de transcriptasa inversa; composicion farmaceutica que contiene a dichos compuestos; y uso del compuesto para tratar la infeccion del vih-1.
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
EA200802209A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA200401436A1 (ru) Ингибиторы протеазы вич для лечения инфекции вич и фармацевтическая композиция
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
EA201000329A1 (ru) Циклические депсипептиды
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
UY30127A1 (es) Derivados de acidos antranilicos fenoxi y feniltio, composiciones farmaceuticas que los contienen y su uso.
ATE511500T1 (de) Sulfonamide als orexin-antagonisten
EP1881825A4 (en) HIV integrase
BR0306927A (pt) Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv
BRPI0915878A2 (pt) sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
UY29648A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
BR0208987A (pt) Composto tricìclicos úteis como inibidores de transcriptase reserva de hiv
BRPI0414199A (pt) inibidores de entrada do vìrus hiv
UY30552A1 (es) Combinaciones farmacologiicas en base a derivados sustituidos de la n-(5-{2-[1,1-dimetil-propilamino]-1-hidroxi-metil}-2-hidroxi-fenil)-metansulfonamida y aplicaciones
EA200801476A1 (ru) Замещенные аминофенилсульфонамидные соединения в качестве ингибиторов протеазы вич
BR0310089A (pt) Inibidores de protease de hiv de sulfonamida benzisoxazol substituìda de largo espectro